

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

March 2007

Vol. 35, No. 3

CONTENTS

SHORT COMMUNICATIONS

Classification of Metabolites with Kernel-Partial Least Squares (K-PLS). MARK J. EMBRECHTS AND SEAN EKINS **325**

Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on *N*- and *S*-Oxygenation Activities. MAKIKO SHIMIZU, HIROSHI YANO, SATOMI NAGASHIMA, NORIE MURAYAMA, JUN ZHANG, JOHN R. CASHMAN, AND HIROSHI YAMAZAKI **328**

Inhibitory Effects of Benzoate on Chiral Inversion and Clearance of *N*^G-Nitro-Arginine in Conscious Rats. XIN YAN-FEI, ZHOU XIANG-JUN, LU JIE, AND WANG YONG-XIANG **331**

CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline. TATSUKI FUKAMI, MIKI NAKAJIMA, HARUKO SAKAI, MIKI KATOH, AND TSUYOSHI YOKOI **335**

Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors. JOHANNA WEISS, DIRK THEILE, NAHAL KETABIKIYANVASH, HEIKE LINDENMAIER, AND WALTER EMIL HAEFELI **340**

In Vitro and in Vivo Determination of Piperacillin Metabolism in Humans. GIULIA Ghibellini, ARLENE S. BRIDGES, CLAUDIA N. GENERAUX, AND KIM L. R. BROUWER **345**

ARTICLES

Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5. NICOLAS

PICARD, NASSIM DJEBLI, FRANÇOIS-LUDOVIC SAUVAGE, AND PIERRE MARQUET **350**

Functional Expression of Stereoselective Metabolism of Cephalexin by Exogenous Transfection of Oligopeptide Transporter PEPT1. KEISUKE MITSUOKA, YUKIO KATO, YOSHIYUKI KUBO, AND AKIRA TSUJI **356**

The Glucuronidation of Δ^4 -3-Keto C19- and C21-Hydroxysteroids by Human Liver Microsomal and Recombinant UDP-glucuronosyltransferases (UGTs): 6 α - and 21-Hydroxyprogesterone Are Selective Substrates for UGT2B7. K. BOWALGAHA, D. J. ELLIOT, P. I. MACKENZIE, K. M. KNIGHTS, AND J. O. MINERS **363**

UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics. ZHIMING WEN, MELANIE N. TALLMAN, SHAZIA Y. ALI, AND PHILIP C. SMITH **371**

The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting. CHARLES J. O'DONNELL, KEN GRIME, PAUL COURTNEY, DEAN SLEE, AND ROBERT J. RILEY **381**

Constitutive and 3-Methylcholanthrene-Induced Rat *ALDH3A1* Expression Is Mediated by Multiple Xenobiotic Response Elements. RICHARD REISDORF AND RONALD LINDAHL **386**

□ Mechanism of the Regulation of Organic Cation/Carnitine Transporter 1 (*SLC22A4*) by Rheumatoid Arthritis-Associated Transcriptional Factor

Continued on next page

RUNX1 and Inflammatory Cytokines. TOMOJI MAEDA, MASAMICHI HIRAYAMA, DAISUKE KOBAYASHI, KEIJI MIYAZAWA, AND IKUMI TAMAI	394	protein-Deficient Mice: P-Glycoprotein Efflux Alters Alfentanil Brain Disposition and Antinoception. J. CORY KALVASS, EMILY R. OLSON, AND GARY M. POLLACK	455
Differential Regulation of Hepatic Transporters in the Absence of Tumor Necrosis Factor- α , Interleukin-1 β , Interleukin-6, and Nuclear Factor- κ B in Two Models of Cholestasis. ANDREW J. LICKTEIG, ANGELA L. SLITT, MELEK C. ARKAN, MICHAEL KARIN, AND NATHAN J. CHERRINGTON	402	Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100. ROSIE Z. YU, TAE-WON KIM, AN HONG, TANYA A. WATANABE, HANS J. GAUS, AND RICHARD S. GEARY	460
Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys. AKIHITO OGASAWARA, TOSHIYUKI KUME, AND EMIKO KAZAMA	410	Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents. KAZUMI KOMORIYA, YUKIO KATO, YUJIRO HAYASHI, KAZUHIRO OHSUYE, RYUICHIRO NISHIGAKI, AND YUICHI SUGIYAMA	469
Expression of the Human <i>UGT1</i> Locus in Transgenic Mice by 4-Chloro-6-(2,3-xylylidino)-2-pyrimidinylthioacetic Acid (WY-14643) and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor α Activation. KATHY SENEKEO-EFFENBERGER, SHUJUAN CHEN, ERIN BRACE-SINNOKRAK, JESSICA A. BONZO, MEI-FEI YUEH, UPENDRA ARGIKAR, JENNY KAEDING, JOCELYN TROTTIER, RORY P. REMMEL, JOSEPH K. RITTER, OLIVIER BARBIER, AND ROBERT H. TUKEY	419	Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes. TAKURO ENDO, MASAOKI BAN, KAZUMA HIRATA, AKITOSHI YAMAMOTO, YOSHIKI HARA, AND YASUNORI MOMOSE	476
CAR2 Displays Unique Ligand Binding and RXR α Heterodimerization Characteristics. SCOTT S. AUERBACH, JOSHUA G. DEKEYSER, MATTHEW A. STONER, AND CURTIS J. OMIECINSKI	428	Helices F-G Are Important for the Substrate Specificities of CYP3A7. NAO TORIMOTO, ITSUKO ISHII, KEN-ICHI TOYAMA, MASAYUKI HATA, KANAKO TANAKA, HITOSHI SHIMOMURA, HIROYOSHI NAKAMURA, NORITAKA ARIYOSHI, SHIGERU OHMORI, AND MITSUKAZU KITADA	484
Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences. ZHIMING WEN, DAVID E. MARTIN, PETER BULLOCK, KUO-HSIUNG LEE, AND PHILIP C. SMITH	440	Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors. SEAN EKINS, DAYNA C. MANKOWSKI, DENNIS J. HOOVER, MICHAEL P. LAWTON, JUDITH L. TREADWAY, AND H. JAMES HARWOOD, JR.	493
Gender-Related Differences in Mycophenolate Mofetil-Induced Gastrointestinal Toxicity in Rats. STEPHAN T. STERN, MELANIE N. TALLMAN, KRISTINI K. MILES, JOSEPH K. RITTER, ROBERT E. DUPUIS, AND PHILIP C. SMITH	449		
Pharmacokinetics and Pharmacodynamics of Alfentanil in P-Glycoprotein-Competent and P-Glyco-			
		LETTER TO THE EDITOR	
		Misuse of the Well-Stirred Model of Hepatic Drug Clearance. JIANGSONG YANG, MASOUD JAMEI, KAREN R. YEO, AMIN ROSTAMI-HODJEGAN, AND GEOFFREY T. TUCKER	501

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: The human CYP51 pharmacophore for $n = 26$ inhibitors generated using Catalyst illustrating one hydrophobe (cyan), one hydrogen bond acceptor (green), and two ring aromatic features (orange). See the article by Ekins et al. on page 493 of this issue.